Lexeo Therapeutics (NASDAQ:LXEO) Insider Sells $34,758.72 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) insider Tai Sandi See sold 3,888 shares of the firm’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $34,758.72. Following the transaction, the insider owned 65,862 shares in the company, valued at approximately $588,806.28. The trade was a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Tai Sandi See also recently made the following trade(s):

• On Monday, August 18th, Tai Sandi See sold 382 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $4.67, for a total value of $1,783.94.

Lexeo Therapeutics Stock Performance

Shares of Lexeo Therapeutics stock opened at $9.58 on Monday. Lexeo Therapeutics, Inc. has a 52-week low of $1.45 and a 52-week high of $11.72. The company’s 50 day moving average price is $5.91 and its 200-day moving average price is $4.41. The stock has a market capitalization of $517.32 million, a price-to-earnings ratio of -2.94 and a beta of 1.66.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.04. As a group, equities research analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on LXEO shares. Chardan Capital raised their target price on Lexeo Therapeutics from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Guggenheim began coverage on Lexeo Therapeutics in a report on Wednesday. They issued a “buy” rating and a $30.00 price objective for the company. Oppenheimer initiated coverage on Lexeo Therapeutics in a research note on Thursday, July 31st. They set an “outperform” rating and a $20.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Lexeo Therapeutics in a report on Wednesday, October 8th. Finally, Leerink Partners raised their price target on Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $18.86.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Balyasny Asset Management L.P. purchased a new stake in shares of Lexeo Therapeutics in the 2nd quarter worth about $16,117,000. Frazier Life Sciences Management L.P. grew its holdings in Lexeo Therapeutics by 363.1% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,424,725 shares of the company’s stock worth $17,787,000 after purchasing an additional 3,469,210 shares during the period. Affinity Asset Advisors LLC grew its holdings in Lexeo Therapeutics by 142.4% in the second quarter. Affinity Asset Advisors LLC now owns 3,589,355 shares of the company’s stock worth $14,429,000 after purchasing an additional 2,108,474 shares during the period. Vestal Point Capital LP increased its stake in shares of Lexeo Therapeutics by 184.1% during the second quarter. Vestal Point Capital LP now owns 3,228,161 shares of the company’s stock valued at $12,977,000 after purchasing an additional 2,091,912 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Lexeo Therapeutics by 654.8% during the first quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock valued at $3,718,000 after purchasing an additional 929,538 shares during the last quarter. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.